Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
OPERATING MARGIN
0.00%
OPERATING MARGIN AVG TTM
0.00%
OPERATING MARGIN AVG 3Y
0.00%
OPERATING MARGIN AVG 5Y
0.00%
OPERATING MARGIN AVG 10Y
0.00%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Rocket Pharmaceuticals, Inc.
Market Cap
$270.80M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$271.81M
Operating Margin
-69.95%
TTM Avg
-45.20%
3Y Avg
-23.79%
5Y Avg
-11.42%
Market Cap
$266.92M
Operating Margin
-2222.45%
TTM Avg
-1882.54%
3Y Avg
-1096.29%
5Y Avg
-863.53%
Market Cap
$266.59M
Operating Margin
0.00%
TTM Avg
-1622.43%
3Y Avg
-1266.60%
5Y Avg
-841.86%
Market Cap
$265.78M
Operating Margin
-775.98%
TTM Avg
-556.52%
3Y Avg
-379.20%
5Y Avg
-295.79%
Market Cap
$264.25M
Operating Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
Operating Margin
-59.68%
TTM Avg
-91.28%
3Y Avg
-192.69%
5Y Avg
-176.13%
Market Cap
$261.43M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5599.55%
5Y Avg
-3879.66%
Market Cap
$261.27M
Operating Margin
-247.44%
TTM Avg
-835.51%
3Y Avg
-417.75%
5Y Avg
-611.14%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | $270.80M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | -69.95% | -45.20% | -23.79% | -11.42% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -2222.45% | -1882.54% | -1096.29% | -863.53% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | 0.00% | -1622.43% | -1266.60% | -841.86% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -775.98% | -556.52% | -379.20% | -295.79% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -59.68% | -91.28% | -192.69% | -176.13% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -5599.55% | -3879.66% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -247.44% | -835.51% | -417.75% | -611.14% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
Operating Margin
0.0%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
